Extracorporeal affinity systems and immunoadsorption therapies

Handan Yavuz; Nilay Bereli; Adil Denizli

doi:10.1016/B978-0-12-823971-1.00001-5

Extracorporeal affinity systems and immunoadsorption therapies

Division of Biochemistry

Research output: Chapter in Book/Report/Conference proceeding › Chapter › peer-review

Abstract

Since the first applications of extracorporeal therapies for more than 50 years, steady advancements have been achieved, and more recently extracorporeal therapies have been accepted for the removal of potential toxic substances from plasma as well as supportive management for conventional therapies ranging from autoimmune diseases, cancer, acute toxicities, and variety of metabolic diseases. This chapter summarizes some of the applications of extracorporeal therapies based on commercial adsorbents, newly synthesized adsorbents, and immunoadsorbents.

Original language	English
Title of host publication	Nanotechnology for Hematology, Blood Transfusion, and Artificial Blood
Publisher	Elsevier
Pages	41-55
Number of pages	15
ISBN (Electronic)	9780128239711
DOIs	https://doi.org/10.1016/B978-0-12-823971-1.00001-5
Publication status	Published - 1 Jan 2021

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Affinity therapy
Extracorporeal treatment
Immunoadsorbent

Access to Document

10.1016/B978-0-12-823971-1.00001-5

Cite this

@inbook{bc6894a371b448d994833a1b976ba321,

title = "Extracorporeal affinity systems and immunoadsorption therapies",

abstract = "Since the first applications of extracorporeal therapies for more than 50 years, steady advancements have been achieved, and more recently extracorporeal therapies have been accepted for the removal of potential toxic substances from plasma as well as supportive management for conventional therapies ranging from autoimmune diseases, cancer, acute toxicities, and variety of metabolic diseases. This chapter summarizes some of the applications of extracorporeal therapies based on commercial adsorbents, newly synthesized adsorbents, and immunoadsorbents.",

keywords = "Affinity therapy, Extracorporeal treatment, Immunoadsorbent",

author = "Handan Yavuz and Nilay Bereli and Adil Denizli",

year = "2021",

month = jan,

day = "1",

doi = "10.1016/B978-0-12-823971-1.00001-5",

language = "English",

pages = "41--55",

booktitle = "Nanotechnology for Hematology, Blood Transfusion, and Artificial Blood",

publisher = "Elsevier",

address = "Netherlands",

}

TY - CHAP

T1 - Extracorporeal affinity systems and immunoadsorption therapies

AU - Yavuz, Handan

AU - Bereli, Nilay

AU - Denizli, Adil

PY - 2021/1/1

Y1 - 2021/1/1

N2 - Since the first applications of extracorporeal therapies for more than 50 years, steady advancements have been achieved, and more recently extracorporeal therapies have been accepted for the removal of potential toxic substances from plasma as well as supportive management for conventional therapies ranging from autoimmune diseases, cancer, acute toxicities, and variety of metabolic diseases. This chapter summarizes some of the applications of extracorporeal therapies based on commercial adsorbents, newly synthesized adsorbents, and immunoadsorbents.

AB - Since the first applications of extracorporeal therapies for more than 50 years, steady advancements have been achieved, and more recently extracorporeal therapies have been accepted for the removal of potential toxic substances from plasma as well as supportive management for conventional therapies ranging from autoimmune diseases, cancer, acute toxicities, and variety of metabolic diseases. This chapter summarizes some of the applications of extracorporeal therapies based on commercial adsorbents, newly synthesized adsorbents, and immunoadsorbents.

KW - Affinity therapy

KW - Extracorporeal treatment

KW - Immunoadsorbent

UR - https://www.scopus.com/pages/publications/85127694333

U2 - 10.1016/B978-0-12-823971-1.00001-5

DO - 10.1016/B978-0-12-823971-1.00001-5

M3 - Chapter

AN - SCOPUS:85127694333

SP - 41

EP - 55

BT - Nanotechnology for Hematology, Blood Transfusion, and Artificial Blood

PB - Elsevier

ER -

Extracorporeal affinity systems and immunoadsorption therapies

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this